• Immunoglobulins have been used on-and off-label for decades to treat diseases of the immune system -most often for autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP) and immunodeficiencies such as primary immune deficiency disorder (PIDD).
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• US payers indicated that IgG products are typically managed with a prior authorization based on indication and that confirmed diagnosis is a critical component of the prior authorization procedure.
• US payers stated that even when IgG products have different FDA-approved indications, prior authorization does not differentiate IgG products due to different labeled indications or routes of administration.
• Fifty-six percent of US payers indicated that failure of oral immunosuppressants and/or steroids was required prior to treatment with IgG.
• US payers whose plan did not require prior treatment failure before IgG, indicated that IgG is typically not a primary treatment of choice by patients.
-For these health plans, there is not a strong perceived need to manage IgG with treatment failure requirements.
• IgG products are primarily handled as part of medical benefits; however, several US payers indicated that management by specialty pharmacy may have some cost savings due to bulk purchasing power and minimizing buy-and-bill at the local level.
• US payers were asked specifically about coverage status and tier placement of specific IgG products (Carimune, Gamunex, Gammagard, Octagam, and Privigen) used in treating CIDP and PIDD.
-Across all health plans surveyed, all IgG products were covered on the highest tier (due to drug price) for both indications with minimal preferred products.
RESULTS

Unlikely 11%
Maybe 22% Yes 67% Figure 4 . Do you believe cost differences (e.g., drug costs, administration costs) to your health plan exist associated with intravenous compared with subcutaneous IgG?
• Payers generally thought that there could be some cost savings due to the route of administration of IgG (subcutaneous vs. intravenous) in the treatment of PIDD (Figure 4 ).
-Payers hypothesized that subcutaneous IgG could save costs due to its home administration; however, US payers had two important caveats.
• SCIg can be administered at home, however a significant portion of patients continue administration with assistance from a health care professional.
• SCIg has a higher acquisition cost, which affects total cost of IgG administration.
• US payers overwhelmingly considered IgG products to be interchangeable therapeutic equivalents from the perspective of the health plan (Figure 1 ).
-Four payers indicated that there could be minor differences and preferences for specific IgG products by the treating physician and/or the patient, but only one US payer indicated that these differences were significant enough to consider the IgG products not to be therapeutic equivalents. • Eight of nine payers considered the site of administration to be paramount to cost savings among patients receiving IgG.
-The general consensus site of administration preference for IgG was at a health clinic, at an infusion center under contract with the health plan, or at home.
-Uncontracted infusion centers and hospitals can have significant impacts on the costs to the health plan and the patient's out-of-pocket expenses.
• In comparison to site of administration, payers did not consider reduced length of infusion time to have a significant impact on costs ( Figure 5 ).
• US payers are willing to consider outcomes data examining administration costs for IgG products (e.g., reduced chair time) (Figure 6 ).
-Outcomes studies need to be unbiased and include a comparison of aggregate costs in order for US payers to fully consider the results in their decision-making process.
Unlikely 22%
Maybe 45% Yes 33% Figure 6 . Would data illustrating reduced administration costs (e.g., reduced chair time) for one IgG product over another be of interest for decision making for your health plan?
• When asked what types of studies US payers thought could be valuable for decision making;
-Collection of resource utilization, variations of care that impact costs, and head-to-head comparisons were most often mentioned. Understanding the cost differences among different IgG indications was also highlighted.
• Appropriate outcomes studies with unbiased results would be considered by stakeholders, namely, medical and pharmacy directors, pharmacy and therapeutics (P&T) committee members, analytical and contracting departments, and clinical or staff pharmacists.
• US payers are looking for product differentiation first in terms of clinical outcomes and second in terms of net cost differences. If there is no demonstrated differentiation among products, then manufacturers should expect commoditization at some point.
-Manufacturers should be prepared for sophisticated payers looking for ways to improve partnerships with physician groups and accountable care organizations.
-Manufacturers should conduct interviews with a handful of payers to determine their thoughts and foresight and define what economic information they would like to see with respect to any sponsored research or studies conducted. • Payers were asked to rate their level of concern in general about the management of IgG products in their health plan (Figure 2 ).
-US payers cited the following areas of concern:
• IgG price • Payers were queried about their concern level for various aspects of IgG product use.
-US payers are most concerned with the price of IgG products, followed by off-label use and site(s) of care for IgG administration. Reimbursement methods and the supply of IgG products are less concerning for US payers (Figure 3 ).
• Three of nine US payers surveyed indicated that they have contracts in place for specific IgG products.
-US payers indicated that there are likely some cost savings with IgG products that could be realized by establishing exclusive contracts, but with competing priorities, other cost-savings areas are currently garnering more attention.
